LGALS3 and cardiovascular disorder: Recent advances in the development of galectin-3 inhibitors for other conditions, such as idiopathic pulmonary fibrosis and cardiovascular diseases, provide a rationale for investigating their application in PCOS management (Ahmed et al., 2023).